Abstracts tagged "cardiovascular disease and cholesterol"

Abstract Number: 1270 • 2012 ACR/ARHP Annual Meeting
Role of Inflammation, Serologic Status and Low Density Lipoprotein in Coronary Heart Disease Among Patients with Rheumatoid Arthritis: Data From the National Veterans Health Administration
Iris Navarro-Millan¹, Shuo Yang², Scott L. DuVall³, Lang Chen⁴, John Baddley⁵, Grant W. Cannon⁶, Elizabeth S. Delzell⁷, Jie Zhang⁸, Monika M. Safford⁹, Nivedita M. Patkar¹⁰, Ted R. Mikuls¹¹, Jasvinder A. Singh¹² and Jeffrey R. Curtis⁸, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁷Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, ¹¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹²Department of Medicine, University of Alabama, Tuscaloosa, AL
Background/Purpose: Rheumatoid arthritis (RA) increases the risk for coronary heart disease and ischemic events like myocardial infarction (MI). The association between traditional cardiovascular risk factors in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].